Why insider trading matters?

If management teams do not own any relevant stakes in the companies they guide, they may not be focused on creating wealth for shareholders to the same degree, compared to those that see their personal wealth increase when share prices rise.

- Klaus Gugler, Economist
Aimmune Therapeutics, Inc. (AIMT)
Sector: Healthcare; Industry: Biotechnology

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2018-02-26 FALBERG KATHRYN E Director Buy 30,000 $32.00 $960,000 No
2015-08-11 FALBERG KATHRYN E Director Buy 25,000 $16.00 $400,000 No

Insider Smart

Ovintiv Inc (OVV) - Insiders of OVV have been HEAVILY accumulating shares in March with a sub-$3 cost. And the stock is now $11. An awesome 400% gain can't be missed if you found it was heavily accumulated earlier.

Insider Smart

Axsome Therapeutics, Inc (AXSM) - AXSM shows the power of an #allgreen stock, no insider selling, great management great company, if you follow the insiders last year and pick up around $25, the 52 week high is $100+.